Global Inflammatory Bowel Disease Market 2022-2028

Global Inflammatory Bowel Disease Market 2022-2028

Global inflammatory bowel disease (IBD) drugs market was valued at $21.6 billion in 2021 and is anticipated grow at CAGR of 4.7% during the forecast period (2022-2028). IBD causes inflammation or swelling in the intestines or broadly in the digestive tract. This inflammation prevails with chronic pain in the digestive tract. Poor appetite, diarrhea, and poor digestion are signs of IBD. The rising prevalence of Crohn’s disease and ulcerative disease across the globe is expected to drive market growth over the forecast period. According to Crohn’s and colitis foundation of the US, every year around 70,000 cases of IBD are diagnosed in the US. Medicines and drugs are introduced for the effective treatment of IBD. Moreover, increasing adoption of biologics for the treatment and the presence of strong pipeline drugs such as upadacitinib, risankizumab, tofacitinib, ustekinumab, and others is anticipated to boost the market growth in the coming years. For instance, in May 2021, the Food and Drug Administration (FDA) of the US has approved the Zeposia drug for the treatment of ulcerative colitis. This drug was approved after a trial of 10 weeks.

Impact of COVID-19 Pandemic on Global Inflammatory Bowel Disease Drugs Market

COVID-19 pandemic has affected every sector of the world. The health sector saw a downfall during COVID-19 as necessary treatment was not available to people during this time. Hospital facilities and drug stores were not in operation, so this market experienced a downfall during this time. IBD medicines are taken as per prescription by health experts who were not available during this time.

Segmental Outlook

The global inflammatory bowel disease drugs market is segmented based on type, drug, and distribution channel. Based on type, the market is segmented into Crohn’s disease and Ulcerative colitis. Based on the drug, the market is sub-segmented into Aminosalicylates, Corticosteroids, TNF Inhibitors, IL Inhibitors, Anti-integrin, JAK Inhibitors, and others. Based on the distribution channel the market is sub-segmented into hospital pharmacy, online pharmacy, and retail pharmacy.Among the above-mentioned segments, the hospital pharmacy segment is going to see considerable growth as people in these serious conditions go to some medical experts. Gastroenterologist operates on any issues is in the digestive tract. They prescribe drugs that are available in hospitals in which that gastro facility is as these are long-term prescription drugs.

Crohn’s Disease Segment is Anticipated to Hold a Prominent Share in the Global Inflammatory Bowel Disease Drugs Market

Crohn’s disease is anticipated to hold a prominent market share in the global Inflammatory bowel disease drugs market during the forecast period. Crohn’s disease can affect any part of the gastrointestinal tract starting from the mouth to the small intestine. It commonly affects the end part where the small intestine ends which is known as the ileum. This disease affects some parts of the GI tract while leaving other parts completely untouched. The entire thickness of the bowel wall can get inflamed if the GI tract is infected by Crohn’s disease. Genetic predisposition, immune system disturbance, and Environmental triggers are the primary cause of Crohn’s disease. For instance, in Feb 2021, Scientists from Ann & Robert H Lurie Children’s hospital in Chicago have demonstrated a nano therapy that will be helpful in reducing intestine inflammation in serious Crohn’s disease.

Regional Outlooks

The global inflammatory bowel disease drugs market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). In Asia Pacific, the market for inflammatory bowel disease treatment is anticipated to grow at the fastest rate over the forecast period. The increasing prevalence of Crohn’s disease and ulcerative colitis in the region’s major economies and rising novel drug approval are expected to drive the regional market growth during the forecast period.

North America is Estimated to Hold the Major Share in the Global Inflammatory Bowel Disease Drugs Market

Geographically, it is anticipated that the major share of the market will be taken by North America and this region will lead during the forecast period. People with inflammatory bowel disease are increasing at a consistent rate in North America. As per Statista, there were around 2.5 million people with Inflammatory bowel disease in the US in the year 2020. It is estimated that this figure will rise to 3.5 million by the year 2030. A major reason for the prevalence of IBD in this region is decreasing immunity among people. When outside bacteria and fungi enter the human intestine, our immune system protects our gut. People with weak immunity are more likely to get affected. For instance, in Jan 2022, M.Ellen Kuenzig from the hospital of sick children in Toronto and his fellow mates conducted a review to examine the prevalence of IBD in children below 21. They found that the prevalence of IBD was highest in North America. This review was published in the journal Gastroenterology.

Market Players Outlook

The major companies serving the global inflammatory bowel disease drugs market include AbbVie Inc., Biogen, Johnson & Johnson Services, Inc., Amgen Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Pfizer Inc, Mergers and acquisitions, new product launches, business expansion, partnership collaboration are done by market players in this field. For instance, in November 2021, an application has been submitted by AbbVie to the European medicine agency for the approval of Risankizumab which will be used for the treatment of Crohn’s disease in patients above 16 years.